SUPPRESSIVE LONG-TERM ANTIVIRAL MANAGEMENT OF HEPATITIS C VIRUS (HCV) AND HIV

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这是一项第二阶段的开放式研究，旨在研究长期服用聚乙二醇化干扰素α2a(聚乙二醇化干扰素-2a)是否能降低合并感染丙型肝炎病毒/艾滋病病毒的受试者的肝纤维化进展速度。接受过丙型肝炎病毒治疗的受试者和之前接受过治疗的受试者都将被纳入研究。预计全国将有多达180名受试者参加，该网站将招募10名受试者。研究持续时间为72至96周，根据研究对象的参与情况，需要进行约18次访问。研究程序将包括身体检查、血液和尿液测试、几项结果评估、以及EKG(如果有指示)、眼睛检查(如果有)和肝脏活检。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a Phase II, open-label study designed to study whether long-term maintenance with pegylated-interferon alfa 2a (PEG-IFN) reduces the rate of liver fibrosis progression in subjects with HCV/HIV co-infection. Both HCV treatment na¿ and previously treated subjects will be enrolled. Up to 180 subjects nationwide are expected to participate with ten subjects targeted for recruitment at this site. The study duration will be between 72 and 96 weeks and will require about 18 visits depending on which arm of the study subjects participate. Study procedures will include physical exams, blood and urine tests, several outcomes assessments, and EKG (if indicated), an eye exam (if indicated), and liver biopsies.